Kite Pharma (KITE) on Watch as Juno Trial Placed on Clinical Hold
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Kite Pharma (NASDAQ: KITE) on watch as Juno Therapeutics, Inc. (Nasdaq: JUNO) announced that it has voluntarily placed on hold the Phase II clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia, known as the “ROCKET” trial. The clinical hold was initiated after two patients suffered cerebral edema earlier this week. One patient died and as of last night the other is not expected to recover.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kite Pharma (KITE) Presents Data from ZUMA-1 Trial in NHL; Primary Endpoint of ORR Met
- Twitter (TWTR) Shares Continue Higher
- Western Digital (WDC) volatility flat into shares rallying on upbeat analyst day and raised guidance
Create E-mail Alert Related CategoriesFDA, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!